Article

DAS181 treatment of severe parainfluenza type 3 pneumonia in a lung transplant recipient

Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington, USA.
Transplant Infectious Disease (Impact Factor: 1.98). 12/2012; 15(1). DOI: 10.1111/tid.12045
Source: PubMed

ABSTRACT Parainfluenza virus (PIV) may cause life-threatening pneumonia in lung transplant patients and there are no proven effective therapies. We report the use of inhaled DAS181, a novel sialidase fusion protein, to treat severe PIV type 3 pneumonia in a lung transplant patient. Treatment was well tolerated and associated with improvement in oxygenation and symptoms, along with rapid clearance of PIV. DAS181 should be systematically evaluated for treatment of PIV infection in transplant recipients.

0 Bookmarks
 · 
89 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Parainfluenza infection is a cause of significant morbidity and mortality in allogeneic hematopoietic stem cell transplant (HSCT) patients. DAS181 is a novel antiviral agent with activity against influenza and parainfluenza. We report the first 2 cases, to our knowledge, of successful DAS181 use in ventilated HSCT patients with severe parainfluenza lung disease.
    Transplant Infectious Disease 01/2014; DOI:10.1111/tid.12177 · 1.98 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Observational data suggest that the treatment of influenza infection with neuraminidase inhibitors decreases progression to more severe illness, especially when treatment is started soon after symptom onset. However, even early treatment might fail to prevent complications in some patients, particularly those infected with novel viruses such as the 2009 pandemic influenza A H1N1, avian influenza A H5N1 virus subtype, or the avian influenza A H7N9 virus subtype. Furthermore, treatment with one antiviral drug might promote the development of antiviral resistance, especially in immunocompromised hosts and critically ill patients. An obvious strategy to optimise antiviral therapy is to combine drugs with different modes of action. Because host immune responses to infection might also contribute to illness pathogenesis, improved outcomes might be gained from the combination of antiviral therapy with drugs that modulate the immune response in an infected individual. We review available data from preclinical and clinical studies of combination antiviral therapy and of combined antiviral-immunomodulator therapy for influenza. Early-stage data draw attention to several promising antiviral combinations with therapeutic potential in severe infections, but there remains a need to substantiate clinical benefit. Combination therapies with favourable experimental data need to be tested in carefully designed aclinical trials to assess their efficacy.
    The Lancet Infectious Diseases 09/2014; 14(12). DOI:10.1016/S1473-3099(14)70821-7 · 19.45 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background. Parainfluenza virus (PIV) commonly infects patients following hematopoietic cell transplantation (HCT), frequently causing lower respiratory tract disease (LRD). The definition of LRD significantly differs among studies evaluating the impact of PIV after HCT. Methods. We retrospectively evaluated 544 HCT recipients with laboratory-confirmed PIV and classified LRD into three groups: possible (PIV detection in upper respiratory tract with new pulmonary infiltrates with/without LRD symptoms), probable (PIV detection in lung with LRD symptoms without new pulmonary infiltrates), and proven (PIV detection in lung with new pulmonary infiltrates with/without LRD symptoms). Results. Probabilities of 90-day survival after LRD were 87%, 58% and 45% in possible, probable and proven cases, respectively. Patients with probable and proven LRD had significantly worse survival than those with upper respiratory tract infection (probable; HR, 5.87; p<0.001, proven; HR, 9.23; p<0.001), while possible LRD did not (HR 1.49; p=0.27). Among proven/probable cases, oxygen requirement at diagnosis, low monocyte counts and high-dose steroid use (>2 mg/kg/day) were associated with high mortality in multivariable analysis. Conclusions. PIV LRD with viral detection in lungs (proven/probable LRD) was associated with worse outcomes compared with that with viral detection in upper respiratory samples alone (possible LRD). This new classification should impact clinical trial design and permit comparability of results among centers.
    Clinical Infectious Diseases 03/2014; 58(10). DOI:10.1093/cid/ciu134 · 9.42 Impact Factor